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Ras proteins mediate PI3K activation through direct binding to p110 catalytic subunits. However, it is unclear
when and where this interaction occurs. In this issue of Cancer Cell, Castellano and colleagues report that
KRAS-driven lungcancers require theRas-p110a interaction for full activationofPI3Kand tumormaintenance.Ras proteins activate multiple effector
pathways. Among the Ras superfamily,
only the forms of Ras that play a direct
role in cancer (H-, N-, and K-Ras) activate
Raf kinases and the MAPK cascade, sug-
gesting this effector pathway is critical
to transformation. However, these Ras
proteins also bind and activate other
effectors, including RalGDS and type I
phosphoinositide 30 kinase (PI3K). Dis-
secting the contributions of these interac-
tions in normal cells and in cancer is an
ongoing challenge.
The role of Ras proteins in regulating
PI3K has been particularly complicated,
because these kinases can be activated
by multiple upstream signals, some of
which depend on cooperation with Ras
proteins, whereas others do not. In addi-
tion, while H-, N-, and K-Ras activate
p110a and p110g subunits of PI3K (Rodri-
guez-Viciana et al., 2004), the closely
related R-Ras proteins activate p110a,
p110g, and p110d of PI3Ks (Marte et al.,
1997), and p110b is regulated by Ras’
cousins, RAC1 and CDC42 (Yang et al.,
2012). Thankfully, after nearly 20 years of
research, we are now getting a clearer
picture of precisely how and when Ras
proteins mediate PI3K activation in
normal cells and cancer.
One useful contribution has come from
the use of Ras mutants that are defective
in PI3K binding but retain other effector
functions. Using this approach, Shannon
and colleagues showed that a K-Ras
mutant that can’t bind PI3K can still
drive T-lineage acute lymphoblastic leu-
kemias, but loss of PTEN compensates
for the lack of Ras-p110a binding in
these tumors (Shieh et al., 2013). This
makes a strong case for an essential
role for Ras activation of PI3K in these
cancers.562 Cancer Cell 24, November 11, 2013 ª20In this issue of Cancer Cell, Castellano
et al. (2013) have taken the complemen-
tary approach and derived a Ras binding
domain (RBD) mutant of p110a that fails
to bind Ras but retains enzymatic activity.
Mice homozygous for the RBD mutation
often die shortly after birth due to
lymphatic defects, but surviving pups
can reach adulthood with no further
defects (Gupta et al., 2007). In most
normal tissues, Ras is therefore dispens-
able for PI3K activation. However, these
mutant mice fail to develop K-Ras driven
lung tumors and H-Ras driven skin can-
cer, demonstrating that tumor initiation
by oncogenic Ras requires Ras-p110a
interaction.
Castellano et al. (2013) have now asked
whether this direct interaction is also
required for tumor maintenance in the
KRASLA2 model of lung cancer. Cre re-
combinase was conditionally expressed
during tumorigenesis to excise a wild-
type PIK3CA allele, resulting in the
expression of a single RBD mutant allele.
Loss of Ras-p110a binding in established
tumors resulted in partial tumor regres-
sion and prolonged cytostasis. Total
removal of p110a through Cre-mediated
excision phenocopied these results.
These elegant experiments show that,
in this model, PI3K activity is essential
for tumor maintenance and this activity
requires Ras-p110a binding.
These studies add to an emerging
model that suggests a spectrum of
PI3K activity can be assembled through
the additive contributions of numerous
PI3K activators, including Ras (Figure 1).
In normal tissues, moderate levels of
PI3K activity are required to maintain
homeostasis. This is likely mediated
through the transient activation of
receptor tyrosine kinases (RTKs) and13 Elsevier Inc.G protein-coupled receptors (GPCRs),
which bind and activate PI3K directly
or through adaptor proteins and often
require coordinated input from a host
of Ras and Rho GTPases to facilitate
multiple normal cellular functions (Fritsch
et al., 2013; Rodriguez-Viciana et al.,
2004).
In the oncogenic K-Ras setting, tumor
cells face challenging growth, survival,
and metabolic demands, all of which
require high PI3K activity. As Castellano
et al. (2013) show, one effective means
of achieving high, sustained PI3K activity
is through binding of Ras to p110a. This
interaction induces a conformational
change in p110a, which opens and
orients the active site toward its lipid
substrate (Pacold et al., 2000) and may
help to stabilize the enzyme at the plasma
membrane. In their model system, it is
likely that mutant K-Ras is the major Ras
protein responsible for PI3K activation,
but other wild-type Ras proteins (H-, N-,
or R-Ras) that bind to p110a may also
contribute to PI3K activation.
PI3K activation can also be driven by
RTK signaling, often working in collabora-
tion with Ras. In K-Ras mutant human
colorectal (Ebi et al., 2011) and lung
(Molina-Arcas et al., 2013) cancer cell
lines, IGF-1R was predominantly respon-
sible for PI3K activation through binding
to IRS adaptor proteins, with K-Ras
making a relatively minor contribution.
Very likely, it is the additive effect of both
Ras- and receptor-mediated p110 acti-
vation that achieves PI3K levels high
enough for tumor growth. These signals
can be further amplified through loss of
PTEN. The fact that alternative means
of PI3K activation persist in the context
of oncogenic K-Ras may be related to
the observation that cells can lose their
Figure 1. Multiple Inputs Lead to Activation of PI3K in Tumors
In normal tissue, PI3K is activated by RTKs and GPCRs through direct binding to receptors or adaptors, and its activity can be modulated by active Ras and
Rho GTPases. In tumor tissues, there is a demand for increased PI3K activity. Cancer cells can achieve this through three major mechanisms: (1) enhanced
Ras-binding to p110a; (2) increased RTK activation and recruitment of PI3K through adaptor proteins; and (3) microenvironmental triggers, which can further
activate receptors and PI3K-binding GTPases. These three mechanisms likely act in concert and vary in intensity depending on the tissue type.
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in K-Ras, PTEN, and PI3K, which occur
in colorectal and endometrial cancers,
further suggest that Ras-mediated PI3K
activation alone is not enough, and addi-
tive inputs are required.
The role of Ras proteins in activating the
MAPK pathway, however, is uncontested,
and MEK represents a potential target
for treatment of Ras mutant cancers.
Combination treatment with MEK and
PI3K inhibitors are effective in treating
K-Ras mutant lung cancers in mice.
Accordingly, Castellano et al. (2013)
show that treatment of p110aRBD mice
with a MEK inhibitor or p110aWT mice
with MEK inhibitor and PI3K inhibitor
enhanced tumor regression to near abla-
tion. Interestingly, the toxic effects of
combined MEK and PI3K inhibitors were
severe in the p110aWT mice, but MEK
inhibition in p110aRBD mice was muchbetter tolerated, indicating that drugs
that disrupt Ras-PI3K binding could
potentially be more tumor selective and
systemically less toxic when administered
in combination with MEK inhibitors. While
the complexities of Ras and PI3K are
being unravelled, new therapeutic oppor-
tunities are being presented.REFERENCES
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